Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Neuroscience Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for TENM2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | TENM2 ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View TENM2 Products |
| Gene Delivery | TENM2 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. High-titer transduction ready. |
View TENM2 Products |
| Benchmark Ab | Anti-TENM2 Recombinant Antibody Recombinant positive control for assay validation. Sequence Verified. |
View TENM2 Products |
| Validator | TENM2 siRNA Set For knockdown verification. High knockdown efficiency guarantee. |
View TENM2 Products |
| Related Target A | ADGRL1 Latrophilin-1; key synaptic adhesion ligand interacting directly with TENM2. |
View ADGRL1 Products |
| Related Target B | TENM4 Subfamily homolog; crucial counter-screening target to ensure monoclonal antibody specificity. |
View TENM4 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Extracellular Domain Complexity (~2500 aa) | Truncated and domain-specific recombinant proteins (EGF-like, NHL domains) with Theoretical MW validation. |
| Subfamily Off-Target Cross-Reactivity (TENM1-4) | Homolog panel proteins (TENM1, TENM3, TENM4) strictly verified by mass spectrometry for counter-screening. |
| Lack of Controls | Sequence-verified clinical benchmark antibodies available as assay positive controls. |
| False Positives | Sequence-specific siRNA sets included for target knockdown validation. |
Live TENM2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for TENM2 therapeutics is intensifying, with major players shifting focus from traditional mAbs to antibody-drug conjugates (ADCs) and synaptic-targeting biologics. As first-generation therapies reach the clinic, the next wave of R&D is targeting specific extracellular domains involved in ligand binding to minimize systemic toxicity while maximizing therapeutic efficacy in solid tumors and neurological disorders.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ADC | Oncology Biotechs | Ovarian Cancer, Glioma | Internalization Assay (Need high-purity ECD-Fc with native glycosylation) |
| Monoclonal Antibody | Neuroscience Institutes | Synaptic Disorders, Neurodegeneration | Ligand-Blocking Assay (Need sequence-verified ADGRL1/LPHN1 interaction proteins) |
| CAR-T | Cell Therapy Developers | Solid Tumors | Specificity Validation (Need Lentivirus for Stable Cell Line generation) |